Gilead’s $11.5B Bet: What Two Companies Saw in One Week
Gilead Sciences disclosed $11.5 billion in acquisition charges for three deals, notably Ouro Medicines and Tubulis, on May 7, 2026. In the same week UCB paid $2.2 billion for Candid Therapeutics, a company with an almost identical dual‑target autoimmune platform. Both firms are betting on drugs that treat hard‑to‑manage autoimmune disorders and an ovarian‑cancer indication that disproportionately affect women. The parallel, high‑value moves signal that institutional capital is validating the underlying science before pivotal Phase 3 data are released.
Is Women’s Health a Good Investment Opportunity for Private Wealth?
Women’s health accounts for just 6% of private healthcare investment despite representing half the global population, creating a pronounced supply gap. At the same time, women are set to inherit roughly 70% of the $124 trillion wealth transfer projected over the...